title: Oral delivery of diabetes peptides - Comparing standard formulations incorporating functional excipients and nanotechnologies in the translational context.
abstract: While some orally delivered diabetes peptides are moving to late development with standard formulations incorporating functional excipients, the demonstration of the value of nanotechnology in clinic is still at an early stage. The goal of this review is to compare these two drug delivery approaches from a physico-chemical and a biopharmaceutical standpoint in an attempt to define how nanotechnology-based products can be differentiated from standard oral dosage forms for oral bioavailability of diabetes peptides. Points to consider in a translational approach are outlined to seize the opportunities offered by a better understanding of both the intestinal barrier and of nano-carriers designed for oral delivery.
authors.affiliation: Drug Delivery Technologies and Innovation, Pharmaceutical Sciences Operations, Lead Generation and Candidate Realization, Sanofi Research and Development, Vitry-sur-Seine, France.
authors.forename: Harivardhan Reddy
authors.initials: HR
authors.lastname: Lakkireddy
authors.affiliation: Diabetes Division, Sanofi Research and Development, Frankfurt, Germany.
authors.forename: Matthias
authors.initials: M
authors.lastname: Urmann
authors.affiliation: Diabetes Division, Sanofi Research and Development, Frankfurt, Germany.
authors.forename: Melissa
authors.initials: M
authors.lastname: Besenius
authors.affiliation: Diabetes Division, Sanofi Research and Development, Frankfurt, Germany.
authors.forename: Ulrich
authors.initials: U
authors.lastname: Werner
authors.affiliation: Diabetes Division, Sanofi Research and Development, Frankfurt, Germany.
authors.forename: Torsten
authors.initials: T
authors.lastname: Haack
authors.affiliation: Disposition Safety and Animal Research, Sanofi Research and Development, Montpellier, France.
authors.forename: Priscilla
authors.initials: P
authors.lastname: Brun
authors.affiliation: Analytical Sciences, Lead Generation and Candidate Realization, Sanofi Research and Development, Montpellier, France.
authors.forename: Jean
authors.initials: J
authors.lastname: Alié
authors.affiliation: Pharmaceutical Sciences Operations, Lead Generation and Candidate Realization, Sanofi Research and Development, Montpellier, France.
authors.forename: Brigitte
authors.initials: B
authors.lastname: Illel
authors.affiliation: Pharmaceutical Sciences Operations, Lead Generation and Candidate Realization, Sanofi Research and Development, Montpellier, France.
authors.forename: Laurent
authors.initials: L
authors.lastname: Hortala
authors.affiliation: Pharmaceutical Sciences Operations, Lead Generation and Candidate Realization, Sanofi Research and Development, Montpellier, France.
authors.forename: Rachel
authors.initials: R
authors.lastname: Vogel
authors.affiliation: Drug Delivery Technologies and Innovation, Pharmaceutical Sciences Operations, Lead Generation and Candidate Realization, Sanofi Research and Development, Vitry-sur-Seine, France. Electronic address: didier.bazile@sanofi.com.
authors.forename: Didier
authors.initials: D
authors.lastname: Bazile
mesh_terms: D000284:Administration, Oral; D000818:Animals; D003920:Diabetes Mellitus / Q000378:metabolism*; D016503:Drug Delivery Systems; D005079:Excipients / Q000008:administration & dosage / Q000737:chemistry* / Q000493:pharmacokinetics; D006801:Humans; D050997:Nanomedicine; D010455:Peptides / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D057170:Translational Research, Biomedical
chemical_list: D005079:Excipients; D010455:Peptides